BMS-986331

BMS-986331 is an investigational small molecule drug developed by Bristol Myers Squibb. It acts as an agonist of the formyl peptide receptor 2 (FPR2), a G protein-coupled receptor involved in the resolution of inflammation and immune modulation. The drug represents a novel mechanism of action targeting FPR2, which may have potential applications in diseases where modulation of inflammation is beneficial. As of now, BMS-986331 has been evaluated in phase 1 clinical trials involving healthy volunteers to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics[1][2][3]. No approved indications or known adverse events have been reported.